Myeloproliferative Neoplasms

Jacqueline S. Garcia, MD, discusses the results of the phase 2 REFINE trial in patients with myelofibrosis.

Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.

Srdan Verstovsek, MD, PhD, discusses the efficacy of momelotinib in myelofibrosis.

Ruben A. Mesa, MD, discusses the rationale for the phase 3 MOMENTUM study in myelofibrosis.

The European Commission has expanded the current indication for avapritinib to include use as a single agent in adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast cell leukemia, following at least 1 systemic treatment.

The panel concludes this discussion with clinical pearls they would like to share with colleagues that treat MPN and MF.

A group of experts share unmet needs in the treatment of MPN and MF while providing information about potential advances that could impact treatment in the future.

Dr Fleischman explains the clinical course she would take with MF treatment and what it would take to change therapies.

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b as a recommended treatment option for adult patients with polycythemia vera.

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

The FDA has granted an accelerated approval to pacritinib (Vonjo) for the treatment of select adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Dr Oh lists the ways MF can and should be monitored.

The panel relays how they would sequence MF therapies, as well as the novel combination therapies that can be used.

A panel of experts share how they select between treatment options for patients with MF.

More upfront therapy options for the MF treatment landscape are discussed, including the safety profiles of these drugs.

Marina Kremyanskaya, MD, PhD, discusses the safety and efficacy of pelabresib in patients with myelofibrosis, additional data from the MANIFEST trial, and other efforts investigating the agent in this disease.

A group of experts explain how to determine treatment for each patient with MF, as well as upfront therapy options.

The panel continues the MF prognosis discussion while also discussing biomarkers and treatment for the disease.

Drs Shammo and Mesa explain the MF prognosis and possible risk factors.

Dr Fleischman provides details about myelofibrosis (MF) and what factors are considered with a diagnosis.

Arpita Gandhi, MD, discusses a subgroup analysis of patients with myelofibrosis who received Orca-T and how this type of therapy could be a game-changer for this patient population.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the current indication for avapritinib to include single-agent use in patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, or mast cell leukemia.

Srdan Verstovsek, MD, PhD, discusses the tolerability of momelotinib in myelofibrosis.

Aaron T. Gerds, MD, MS, discusses emerging agents in myelofibrosis.

The FDA has placed a partial clinical hold on clinical trials evaluating the combination of magrolimab and azacitidine after an apparent imbalance in investigator-reported, suspected unexpected serious adverse reactions observed between study arms.